By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001

Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.

Key Statistics

Ownership: Public

Web Site: Seattle Genetics
Symbol: SGEN


Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 


Company News
Seattle Genetics (SGEN) Highlights Phase I Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At American Society of Hematology Annual Meeting 12/5/2016 11:23:08 AM
Seattle Genetics (SGEN) Highlights Long-Term Follow-Up Data From ADCETRIS┬« (Brentuximab Vedotin) In T-Cell Lymphomas At American Society of Hematology Annual Meeting 12/5/2016 11:10:46 AM
FDA Calls It! Seattle Genetics (SGEN)' Adcetris is a Breakthrough for Lymphoma 11/10/2016 6:59:34 AM
Seattle Genetics (SGEN) And Takeda (TKPYY) Complete Enrollment Of Phase III ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) In Frontline Mature T-Cell Lymphoma 11/8/2016 8:17:48 AM
Seattle Genetics (SGEN) Announces American Society of Hematology 2016 Abstracts Highlighting Company's Expanding Global Leadership In The Development Of Innovative Antibody-Drug Conjugates 11/4/2016 11:11:20 AM
Seattle Genetics (SGEN) Reports Third Quarter 2016 Financial Results 10/28/2016 12:16:47 PM
Seattle Genetics (SGEN) Demonstrates Commitment To Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations At ISHL 2016 10/20/2016 10:16:27 AM
Seattle Genetics (SGEN) Creates New C-Suite Role as it Seeks Profitability 10/18/2016 7:18:14 AM
Share Sale Speculation: Baker Brothers Hedge Fund Registers 44 Million Shares of Seattle Genetics (SGEN) 10/14/2016 6:34:48 AM
Seattle Genetics (SGEN) And Agensys, Inc., An Affiliate Of Astellas (ALPMY), Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress 10/7/2016 11:00:51 AM